Emerging
Jun 23, 20261
71%
SBP Group CEO Tse Outlines Shift from Generics to Drug Innovation
SBP Group CEO Eric Tse announced the company's strategic shift from generic pharmaceuticals to innovative drug development at the World Economic Forum's Annual Meeting of the New Champions in Dalian, reflecting broader industry transformation in China's healthcare sector.
Quick Facts
Who
Eric Tse
What
SBP Group transitioning from generics-focused model to drug development
When
June 23, 2026
Where
Dalian, China
- SBP Group transitioning from generics-focused model to drug development
- CEO discusses outlook for China's healthcare sector
- Company positioning as innovation-focused player
- Eric Tse
- Stephen Engle
SBP Group, one of China's established pharmaceutical companies, is charting a new strategic direction focused on innovative drug development rather than its traditional generics-focused business model. CEO Eric Tse outlined the company's vision during an interview at the World Economic Forum's Annual Meeting of the New Champions in Dalian, speaking with Bloomberg's Stephen Engle.
The transition reflects broader trends in China's healthcare sector as the industry matures and competition in generic drugs intensifies. SBP Group's pivot toward drug development signals the company's ambition to compete in higher-value pharmaceutical segments and respond to evolving market dynamics in China's pharmaceutical landscape.
Tse's remarks at the forum provided insight into how legacy pharmaceutical players in China are repositioning themselves to capitalize on innovation opportunities and adapt to changing regulatory and market conditions in the healthcare industry.
Topics
Why This Matters
This announcement signals a critical industry transformation in China's pharmaceutical sector. As generic drug competition intensifies and profit margins compress, legacy Chinese pharma companies like SBP Group are repositioning toward higher-value drug innovation. This shift indicates China's maturing healthcare ecosystem is now ready to support indigenous innovation, with implications for global drug development, competitive dynamics between Chinese and Western pharmaceutical players, and investment opportunities in Chinese biotech ventures.
Timeline & Sources
Jun 23, 2026
WireSBP Group CEO Eric Tse discusses company's strategic shift from generics to drug innovation at World Economic Forum in Dalian